Muscle Mass is a Key Metric in Cancer Care and GLP-1 Therapy
In this new CURE® interview, Kristin Lupton, PA-C and David Weintritt, MD of Virginia Cancer Specialists explain why preserving muscle on GLP-1 therapy is a matter of durability.
We use cookies to make your visit to our website as pleasant as possible. If you continue to use the website, you agree to our privacy policy and to the use of cookies. More information about cookies and how ImpediMed uses them is available in our Cookie and Privacy Policy.
